NASDAQ:IMMX Immix Biopharma (IMMX) Stock Price, News & Analysis $9.00 +0.16 (+1.81%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$8.99 -0.01 (-0.06%) As of 05/29/2026 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immix Biopharma Stock (NASDAQ:IMMX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immix Biopharma alerts:Sign Up Key Stats Today's Range$8.54▼$9.0650-Day Range$8.15▼$10.6652-Week Range$1.87▼$11.61Volume963,861 shsAverage Volume1.30 million shsMarket Capitalization$489.69 millionP/E RatioN/ADividend YieldN/APrice Target$19.50Consensus RatingModerate Buy Company Overview Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy. The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment. IMX-110 is currently being evaluated in early-phase clinical trials, with initial data assessing safety, tolerability and preliminary signs of clinical benefit. In addition to its flagship program, Immix Biopharma is advancing a pipeline of next-generation myeloid modulators in preclinical development, seeking to expand application across multiple tumor types. Headquartered in the United States, Immix Biopharma operates research and development facilities dedicated to advancing its immuno-oncology platform through early clinical stages. The management team brings together seasoned professionals in oncology drug development and translational research, supported by collaborations with leading academic and clinical institutions. With a commitment to addressing unmet needs in cancer care, Immix Biopharma is positioned to translate innovative science into potential new therapies for patients worldwide.AI Generated. May Contain Errors. Read More Immix Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreIMMX MarketRank™: Immix Biopharma scored higher than 57% of companies evaluated by MarketBeat, and ranked 458th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingImmix Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialImmix Biopharma has a consensus price target of $19.50, representing about 116.7% upside from its current price of $9.00.Amount of Analyst CoverageImmix Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immix Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immix Biopharma are expected to grow in the coming year, from ($0.74) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immix Biopharma is -9.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immix Biopharma is -9.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmix Biopharma has a P/B Ratio of 5.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immix Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.49% of the float of Immix Biopharma has been sold short.Short Interest Ratio / Days to CoverImmix Biopharma has a short interest ratio ("days to cover") of 4.18.Change versus previous monthShort interest in Immix Biopharma has recently increased by 6.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmix Biopharma does not currently pay a dividend.Dividend GrowthImmix Biopharma does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.86 News SentimentImmix Biopharma has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Immix Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for IMMX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immix Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders30.30% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.26% of the stock of Immix Biopharma is held by institutions.Read more about Immix Biopharma's insider trading history. Receive IMMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMMX Stock News HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)May 28 at 7:01 PM | theglobeandmail.comImmix Biopharma (IMMX) Projected to Post Earnings on WednesdayMay 27 at 2:16 AM | americanbankingnews.comMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.May 30 at 1:00 AM | Behind the Markets (Ad)Immix Biopharma, Inc. Closes $140.65 Million Underwritten Registered Offering of Common StockMay 22, 2026 | quiverquant.comQImmix Biopharma Announces Closing of $150 Million Underwritten Offering of Common StockMay 22, 2026 | globenewswire.comImmix rises after mid-stage trial data for AL amyloidosis therapyMay 21, 2026 | seekingalpha.comWhat's going on with Immix Biopharma stock Thursday?May 21, 2026 | msn.comImmix Biopharma Reports 95% Complete Response Rate in NEXICART-2 Trial for AL Amyloidosis PatientsMay 21, 2026 | quiverquant.comQSee More Headlines IMMX Stock Analysis - Frequently Asked Questions How have IMMX shares performed this year? Immix Biopharma's stock was trading at $5.23 at the beginning of 2026. Since then, IMMX shares have increased by 72.1% and is now trading at $9.00. How were Immix Biopharma's earnings last quarter? Immix Biopharma, Inc. (NASDAQ:IMMX) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. When did Immix Biopharma IPO? Immix Biopharma (IMMX) raised $23 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share. Who are Immix Biopharma's major shareholders? Top institutional investors of Immix Biopharma include Janus Henderson Group PLC (8.83%), LGT Fund Management Co Ltd. (0.79%), Sei Investments Co. (0.27%) and Bank of New York Mellon Corp (0.16%). Insiders that own company stock include Ilya M Rachman, Jason Hsu, Gabriel S Morris, Carey Ng and Helen C Adams. View institutional ownership trends. How do I buy shares of Immix Biopharma? Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immix Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE). Company Calendar Last Earnings5/07/2026Today5/30/2026Next Earnings (Estimated)6/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 IMMX's financial health is in the Green zone, according to TradeSmith. IMMX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMMX CIK1873835 Webwww.immixbio.com Phone310-651-8041FaxN/AEmployees9Year Founded2012Price Target and Rating Average Price Target for Immix Biopharma$19.50 High Price Target$23.00 Low Price Target$15.00 Potential Upside/Downside+116.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.24% Return on Assets-59.20% Debt Debt-to-Equity RatioN/A Current Ratio8.75 Quick Ratio8.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book5.81Miscellaneous Outstanding Shares54,410,000Free Float37,924,000Market Cap$489.69 million OptionableOptionable Beta0.12 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:IMMX) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredWhen SpaceX goes public your retirement pays the priceWhen SpaceX files its S-1, institutions will liquidate holdings, rebalance portfolios, and free up capital for...Reagan Gold Group | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
